New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase ...

LONG BEACH, Calif. -- Outcomes in neovascular age-related macular degeneration (nAMD) failed to improve with the addition of ...

Investigators defined an IOP spike as >40 mm Hg or an increase ≥10 mm Hg after injection. The population was older (mean age ...

Iluvien for diabetic macular edema demonstrated longer-lasting intervals between injections and noninferior visual acuity ...

Pavblu, an Eylea HD biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable ...

Patients with challenging diabetic macular edema may achieve anatomical gains and extended dosing intervals with bispecific faricimab.

On July 14, 2025 Fresenius filed two IPR petitions challenging Regeneron’s patents related to aflibercept. Regeneron has not asserted that ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

EyePoint Pharmaceuticals completed enrollment in the LUCIA trial, its second phase 3 trial of Duravyu in patients with wet ...

June 30, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.